Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Core Viewpoint - Quoin Pharmaceuticals Ltd. has filed U.S. and International patent applications for novel topical rapamycin formulations aimed at treating rare diseases, including microcystic lymphatic malformations, venous malformations, and angiofibromas, utilizing its proprietary Invisicare delivery technology [1][3]. Company Overview - Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, with a pipeline that includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa [9]. Product Development - The company is advancing its lead product, QRX003, which is in late-stage clinical testing as a potential treatment for Netherton Syndrome, and believes it could be the first approved treatment for this condition [2][3]. - Quoin is currently enrolling patients in three clinical trials under an open Investigational New Drug (IND) application for QRX003 [4]. Technology and Innovation - The Invisicare delivery technology is designed to enhance the penetration of rapamycin into the dermis, potentially improving clinical efficacy compared to other topical formulations that have underperformed [2][3]. - The company plans to submit IND applications for at least two additional target indications this year and to initiate clinical development promptly [3][7]. Target Indications - The company is focusing on microcystic lymphatic malformations, venous malformations, and angiofibromas as potential indications for its novel topical formulations [1][7]. - Microcystic lymphatic malformations occur in 1 in 6000 to 16,000 patients, while venous malformations have an incidence of 1 to 2 in 10,000 and a prevalence of 1% [5][6].